	It is made available under a CC-BY-NC-ND 4.0 International license .
1 2 3	Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis
4 5	Hongru Du MS ^{1,2, *} , Samee Saiyed MSE ^{1,2} , and Lauren M. Gardner PhD ^{1,2,3}
6	¹ Center for Systems Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
7	² Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD 21218, USA.
8 9	³ Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
10 11	*Corresponding author. Johns Hopkins University, 3400 N. Charles Street, Shaffer 4, Baltimore, MD, 21218, USA. E-mail address: hdu9@jhu.edu (Hongru Du)
12	
13	Abstract
 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 20 	Population-level vaccine efficacy is a critical component of understanding COVID-19 risk, informing public health policy, and mitigating disease impacts. Unlike individual-level clinical trials, population-level analysis characterizes how well vaccines worked in the face of real-world challenges like emerging variants, differing mobility patterns, and policy changes. In this study, we analyze the association between time-dependent vaccination rates and COVID-19 health outcomes for 48 U.S. states. We primarily focus on case-hospitalization risk (CHR) as the outcome of interest, using it as a population-level proxy for disease burden on healthcare systems Performing the analysis using Generalized Additive Models (GAMs) allowed us to incorporate real-world nonlinearities and control for critical dynamic (time-changing) and static (temporally constant) factors. Dynamic factors include testing rates, activity-related engagement levels in the population, underlying population immunity, and policy. Static factors incorporate comorbidities, social vulnerability, race, and state healthcare expenditures. We used SARS-CoV-2 genomic surveillance data to model the different COVID-19 variant-driven waves separately, and evaluate if there is a changing role of the potential drivers of health outcomes across waves. Our study revealed a strong and statistically significant negative association between vaccine uptake and COVID-19 CHR across each variant wave, with boosters providing additional protection during
30 31	the Omicron wave. Higher underlying population immunity is shown to be associated with reduced COVID-19 CHR. Additionally, more stringent government policies are generally
32	associated with decreased CHR. However, the impact of activity-related engagement levels on
აა 34	vulnerability index consistently exhibits positive associations with CHR, while Medicaid
35 36	spending per person consistently shows a negative association. However, the impacts of other static factors vary in magnitude and significance across different waves. This study concludes

37 that despite the emergence of new variants, vaccines remain highly correlated with reduced

- 38 COVID-19 harm. Therefore, given the ongoing threat posed by COVID-19, vaccines remain a
- 39 critical line of defense for protecting the public and reducing the burden on healthcare systems.
- 40
- 41 **Keywords:** COVID-19, vaccination rates, population-level, United States, statistical analysis
- 42
- 43

44 **1. Background**

By March 1st, 2023, the COVID-19 pandemic caused over 102 million reported cases and 1.1 45 46 million deaths in the United States. Vaccine development and distribution have been at the 47 forefront of efforts to combat the impact of the disease. Three vaccines are currently available in 48 the U.S., developed by Pfizer-BioNTech, Moderna, and Johnson & Johnson. Initial randomized 49 clinical trials demonstrated the safety and efficacy of these vaccines, with vaccine efficacies 50 against severe disease (hospitalization and death) ranging from 73.1% to 96.7% [1–3]. The clinical trials were designed to estimate the direct effect of vaccines against severe disease at the 51 52 individual level [4]. However, as vaccines roll out to a broader population, uncertainties such as the emergence of new variants, variable immune responses, the quality of cold-chain storage, and 53 54 other confounding factors can impact a vaccine's efficacy [5]. Hence, evaluating real-world 55 vaccine protection against COVID-19 health outcomes poses a challenge.

Several published studies have attempted to quantify the real-world impact of the COVID-19 56 vaccines on health outcomes. For example, a study in Qatar assessed the vaccines' effectiveness 57 against severe, critical, or fatal Omicron infections using test-negative case-control analysis, and 58 found previous infections and vaccination are effective against symptomatic Omicron infections 59 [6]. An observational study conducted in Israel using national surveillance data showed that the 60 two doses of the Pfizer-BioNTech mRNA vaccines are 97.2% effective in preventing COVID-61 19-related hospitalizations [7]. A Danish study estimated vaccine effectiveness against COVID-62 63 19 hospitalization using a cohort study design, and found that two doses of the vaccine provide 64 high protection against hospitalization for the Alpha and Delta variant, and even higher protection against hospitalization for the Omicron variant [8]. A similar cohort study was applied 65 in Singapore and the United Kingdom to determine whether booster shots reduce the severity of 66 67 COVID-19 infections during the Omicron wave, and found consistent results that the risk of severe COVID-19 outcomes reduced after receiving booster mRNA vaccines [9,10]. 68

69 Most existing literature on the population-level effects of COVID-19 vaccination is based on 70 individual-level data and observational studies. Specifically, these studies relied upon detailed 71 individual-level data to assess the direct effectiveness of vaccination by comparing health 72 outcomes between vaccinated and unvaccinated individuals exposed to the same environment. 73 However, these studies may be subject to confounding by unmeasured factors and inconsistent 74 quality of individual-level data. Further, in the U.S., such high-resolution data is unavailable at the population-level, so alternative strategies must be engaged to evaluate the impact of vaccine 75 at a regional level. 76

One such approach is to rely on compartmental and agent-based models to simulate transmissionand disease outcomes both in the presence and absence of vaccines implementation for the same

79 population. Watson et al applied this method to estimate the impact of varying vaccine uptake rates on mortality across multiple countries and found that vaccines prevented 14.4 million 80 81 COVID-19 deaths in 2021 [11]. However, this approach is subject to many assumptions and is 82 limited in its ability to estimate accurate effectiveness. Alternatively, statistical methods such as time series and regression analysis can be implemented to evaluate the association between 83 vaccination coverage and healthcare outcomes across different locations. One study using this 84 85 strategy evaluated the association between vaccination coverage and the COVID-19 cases growth rate for all 50 U.S. states in the U.S. using a structural nested mean model and found a 1% 86 increase in vaccination coverage was associated with a 1.02% reduction in case growth rate [12]. 87 However, the scope of this study is limited to cases between March and May 2021. Another 88 study utilized linear regression to analyze vaccine coverage and natural immunity in relation to 89 90 mortality during the Delta and Omicron waves. It found that vaccine coverage reduced COVID-19 mortality, but seroprevalence and prior infection rates were not associated with mortality [13]. 91 However, this method has limitations in capturing dynamic changes and non-linear relationships 92 93 between variables. A different study by Bollyky et al [14] applied regression analysis to 94 determine how vaccination coverage amongst other factors (e.g., presence of comorbidities, political partisanship, race, and ethnicity) impacted health outcomes (standardized infections and 95 deaths) in the U.S. at the state level, and determined that higher vaccination rates were associated 96 with lower death rates. The scope of this study varies from ours in its focus on the association 97 between static variables and COVID-19 health outcomes for a fixed time window between 98 99 January 1st, 2020, and July 31st, 2022, while our study expands the analysis by incorporating novel dynamic variables to capture behavioral changes over time, and explicitly evaluating the 100 different variants independently. A recent study evaluated the time-varying relationship between 101 vaccination, mobility, and COVID-19 health outcomes before and after the Omicron waves [15]. 102 103 They found the significance of the vaccine's impact in reducing case rates diminished during the Omicron surge, while its efficacy in lowering case-fatality rates remained substantial throughout 104 105 the pandemic.

106 Our study contributes to the existing literature by prioritizing case-hospitalization risk as the 107 outcome variable, breaking aggregated mobility into activity-related engagement levels, 108 modeling previous infections as a dynamic variable, including an interaction between the 109 completed primary series and booster rate for the Omicron wave, and considering the critical 110 static factors such as comorbidities, social vulnerability, race, and state healthcare expenditures. Despite numerous studies assessing the effectiveness of vaccines, most have not accounted for 111 112 the relative impact of vaccines across different populations and variant waves, while considering 113 dynamic potential confounding factors. Therefore, a more comprehensive understanding of 114 vaccines' impact across diverse populations and COVID-19 waves is crucial in developing 115 informed public health policies that can effectively mitigate the spread of the virus and ensure 116 equitable distribution of healthcare resources.

118 **2. Methods**

119 2.1 Study design

The primary objective of this study is to analyze the association between COVID-19 vaccination 120 rates and COVID-19 case-hospitalization risk (CHR) in the U.S. while controlling for potential 121 122 confounding effects. Time-dependent COVID-19 CHR is chosen as the modeled response 123 variable to gain insights into the factors influencing COVID-19 harm; CHR serves as both a 124 proxy for disease severity at an individual level, and captures the burden on the healthcare 125 system at a population level. We use Generalized Additive Models (GAMs) to perform the 126 analysis because of their ability to capture nonlinear dynamics. Data used include novel dynamic 127 covariates that may potentially contribute to COVID-19 CHR, such as naturally derived 128 immunity from prior COVID-19 infection, local healthcare infrastructure, activity-related 129 engagement levels in the population, and government policies, alongside various static variables 130 that have been identified to be significant in previous studies [14,16,17] such as comorbidities, social vulnerability index (SVI), race, and state healthcare expenditures. By controlling for these 131 132 factors, we aim to provide a more comprehensive understanding of the association between vaccination rate and COVID-19 CHR at the population level. To further elucidate the role of 133 134 potential driving factors, we also model reported case incidence rates (CIR) as a separate 135 response variable and compared the factors associated with COVID-19 transmission versus those 136 associated with COVID-19 CHR. Our framework explicitly captures the spatial variation in the modeled relative associations through a variable transformation procedure (discussed in detail in 137 the methods section). The study was conducted for 48 states in the U.S. for the period between 138 April 19th, 2021, the date at which the vaccines were approved for all adults in the U.S., to March 139 140 1st, 2022. This period covers the pre-Delta (characterized by the predominance of the Alpha 141 variant and other variants), Delta, and Omicron waves of COVID-19, which are each evaluated 142 independently. To distinguish between COVID-19 variant-driven waves, we utilized SARS-143 CoV-2 genomic surveillance data and identified the dominant variant for each state and point in 144 time, to determine time windows so the distinct variant-driven waves can be modeled independently. For the Omicron wave, we also considered the added benefit of booster doses on 145 146 COVID-19 health outcomes. Specifically, we evaluated the interaction between the completed 147 primary series and booster rate on reducing COVID-19 CHR. Results from this analysis help 148 improve our understanding of the real-world relative impact of the available COVID-19 vaccines 149 against COVID-19 CHR at the population-level over time, and can help inform future public 150 health policies to reduce harm.

151

152 2.2 Data sources and collection

We collected state-level time-series data and static variables from publicly available databases. All time-series data were aggregated to the weekly level. A summary of the variables and their respective sources are listed in Table 1, and detailed explanations of each variable are provided in Appendix section 1.2. A 3-week moving average was applied to all time-series variables to mitigate the effects of potential noise and reporting issues, with the exception of the government policy index.

- 159
- 160 Table 1. Summary of dynamic variables in the model.

Variable Name	Variable Description	Source				
Output variables						
Case-hospitalization rate (CHR)	Weekly new admissions of patient with confirmed COVID-19 normalized by reported cases for each state.	[18], [19]				
Reported case-incidence rate (CIR)	Weekly number of confirmed cases normalized by state population.	[18]				
Dynamic input variables						
Partial vaccination rate	Percentage of the total population that received at least one dose of COVID-19 vaccine approved or authorized for use in the United States.	[20]				
Completed primary series rate	Percentage of the population that received the second dose in a two-dose COVID-19 vaccines primary series or one dose of a single-dose COVID-19 vaccine primary series approved or authorized for use in the United States.	[20]				
Booster vaccination rate	Percentage of the total population that received an updated (bivalent) booster dose.	[21]				
Weekly testing rate	Total number of weekly tests conducted for each state normalized by population.	[22]				
Gym visits	Number of weekly visits to gyms per person.	[23,24]				
University visits	Number of weekly visits to universities per person.	[23,24]				
Physician visits	Number of weekly visits to physicians per person.	[23,24]				
Government policy index	Quantitative measure of government policies implemented in response to the COVID-19 pandemic across various domains including health, social, and economic policies.	[25]				
Previous infections	Infections reported within a time window preceding the modeled output, e.g., sum from 4 to 16 weeks ahead of the output variables.	[18]				

162

163	Table 2.	Summary	of static	variables	in the	model.
-----	----------	---------	-----------	-----------	--------	--------

Static input variables	Description	Mean	St.d.	Min	Max	Source
Black proportion	The proportion of the population identified as Black.	0.112	0.019	0.006	0.378	[26]
Social vulnerability index (SVI)	The Social Vulnerability Index utilizes data from the U.S. Census to assess the relative level of social vulnerability in each census tract. By analyzing 14 social factors, the SVI categorizes tracts into four closely interrelated themes and then aggregates them as a single indicator of social vulnerability.	0.468	0.152	0.137	0.771	[27]
Adults at high risk	The proportion of the population over 18 years old is at high risk of serious illness if infected with Coronavirus.	0.383	0.036	0.300	0.493	[28]
Medicaid spending	Total Medicaid spending in thousands of dollars for each state normalized by the population.	1.807	0.550	0.860	3.099	[29]

164

165 2.3 Dynamic variable transformation

To ensure the precise estimation of each dynamic variable's impact, a variable transformation 166 mechanism must be used to account for the effects of time trends in the data. For example, the 167 168 completed primary series rate is always increasing with time for all locations modeled, hence it can be difficult to distinguish how much of the observed associations between vaccination rate 169 and COVID-19 health outcomes are due to the variable interaction or the passage of time. 170 Moreover, the main focus of this study lies in modeling spatial differences and considering 171 172 location-specific variations that influence the observed associations. Consequently, we applied 173 the following transformation to all dynamic variables to remove the time trend and redefine the relative variable (RV_i^t) : 174

$$RV_i^t = \frac{V_i^t}{\frac{1}{n}\sum_j V_j^t}$$

Where RV_i^t represents the transformed variable for state *i* at week *t*, V_i^t represents the original 175 variable for state i at week t without the transformation, $\frac{1}{n}\sum_{j}V_{j}^{t}$ represents the mean of the 176 original variable at week t, over all locations being modeled n, e.g., the national mean across the 177 U.S. A RV_i^t larger than one indicates that state *i* has a higher variable value compared to the 178 national mean at week t, while RV_i^t lower than one indicates that state i has a lower variable 179 value compared to the national mean, at week t. After normalization, the final set of time-180 181 dependent variables included in the analysis are: Relative case-hospitalization rates $(RCHR_i^t)$, relative reported case-incidence rate $(RCIR_i^t)$, relative completed primary series rate $(RCPSR_i^t)$, 182 relative booster rate (RBR_i^t) , relative weekly testing rate $(RWTR_i^t)$, relative gym visits (RGV_i^t) , 183 relative physician visits (RPV_i^t) , relative university visits (RUV_i^t) , relative previous infection 184 (RPI_i^t) , and relative government policy (RGP_i^t) . These newly transformed variables enable an 185 explicit evaluation of the relative association between each of them and the COVID-19 health 186 outcome of interest within a single multi-state model. Moreover, this variable transformation 187 188 procedure facilitates assessing individual state's performance relative to national dynamics. It 189 emphasizes evaluating the expected outcomes when a state's performance diverges from the 190 national average.

191 The dynamic variables, with and without variable transformation, are visually depicted in 192 Appendix figure S2. Among all the variables, the rankings of $RCPSR_i^t$ remain relatively stable 193 across time, as seen in Appendix figure S2b2. This stability indicates a more consistent spatial-194 temporal pattern of variation among vaccination rates across states. On the other hand, all other 195 dynamic variables exhibit more noticeable spatial ranking changes over time. The changing 196 spatial-temporal rankings of other dynamic variables highlight the importance of considering 197 spatial differences through time and evaluating their influence on COVID-19 health outcomes.

198 2.4 Statistical analysis

199 The generalized additive model (GAM) was selected as the statistical model for this analysis because of its ability to capture complex and nonlinear relationships between the set of 200 covariates and the outcome variables of interest in each state. We independently model each 201 202 variant-driven wave during the study period to allow for different driving factors for different 203 variants. To define the variant waves, we clustered each state-week pair based on the dominant circulating variant based on SARS-CoV-2 genomic surveillance data downloaded from GISAID 204 [30]. The three waves are classified as: 1) Pre-Delta Wave, 2) Delta Wave, 3) Omicron Wave, 205 and each state is labeled with its most dominant variant each week to define the windows. 206 207 Details of this classification are described in Appendix section 1.1, and the assignment of state-208 week pairs is shown in Appendix figure S1.

- 209 The primary set of models treat weekly state-level RCHR as the response variable, with separate
- 210 models generated independently for each variant wave, namely Pre-Delta-RCHR, Delta-RCHR,
- and Omicron-RCHR. These three models have the form:

212

$$RCHR_i^t \sim Gamma(\mu, \phi)$$

$$\log(\mu) = \alpha + f_1(RCPSR_i^{t-2}) + f_2(RWTR_i^{t-2}) + f_3(RGV_i^{t-2}) + f_4(RPV_i^{t-2})$$

$$f_5(RUV_i^{t-2}) + f_6(RGP_i^{t-2}) + f_7(RPI_i^t) + \beta_1(Black \ proportion) + \qquad (1)$$

$$\beta_2(SVI) + \beta_3(Adults \ at \ high \ risk) + \beta_4(Medicaid \ spending)$$

213

214 Where α represents the intercept, β_i represent the parametric coefficients of each static variable, 215 and f_i are spline smooth functions of the relative dynamic variables. Additionally, a model is 216 constructed for the Omicron wave, incorporating an interaction between completed primary 217 series and booster rate (Omicron-Booster-RCHR). The Omicron-Booster-RCHR has the form:

218

$$RCHR_{i}^{t} \sim Gamma(\mu, \phi)$$

$$\log(\mu) = \alpha + f_{1}(RCPSR_{i}^{t-2}, RBR_{i}^{t-2}) + f_{2}(RWTR_{i}^{t-2}) + f_{3}(RGV_{i}^{t-2}) + f_{4}(RPV_{i}^{t-2})$$

$$f_{5}(RUV_{i}^{t-2}) + f_{6}(RGP_{i}^{t-2}) + f_{7}(RPI_{i}^{t}) + \beta_{1}(Black \ proportion) + \qquad (2)$$

$$\beta_{2}(SVI) + \beta_{3}(Adults \ at \ high \ risk) + \beta_{4}(Medicaid \ spending)$$

219

Where f_1 represent a smooth interaction function between $RCPSR_i^{t-2}$ and RBR_i^{t-2} . For all the 220 221 mentioned models above, the weekly state-level RCHR is assumed to follow a Gamma 222 distribution with a log link. This choice of the Gamma family accounts for the positively skewed 223 distribution of the outcome variable. We use thin plate regression splines as the smoothing basis 224 for all f_i and set the basis dimension to three to maximize the interpretability of the models. The 225 basis dimension refers to the maximum possible complexity of each smooth term; a large basis 226 dimension could overfit the data and result in highly non-linear relationships between input and 227 outcome variables.

228 To consider the sequential process of infection leading to hospitalization we introduce a time lag between each of the input variables relative to the outcome variable, which is denoted by the 229 230 superscript. The timeline of this model is introduced as follows: the modeled relative casehospitalizations rate $(RCHR_i^t)$, occur at time t. Infections resulting in hospitalization, are 231 assumed to occur at time t-2, to account for a one week incubation period [31], and one 232 233 additional week between symptoms onset and hospitalization [32]. Note, this timeline aligns with 234 the definition of the CHR variable, which is normalized by the number of reported infections one 235 week prior, which assumes a one week delay between when infection occurred and when it is reported. To accurately reflect the conditions presented at the time of infection, each of the 236 variables related to vaccination $(RCPSR_i^{t-2})$, activity-related engagement levels (RGV_i^{t-2}) , 237 RPV_i^{t-2} , RUV_i^{t-2}), policy (RGP_i^{t-2}) , and testing $(RWTR_i^{t-2})$ are also lagged by two weeks 238 239 relative to the case-hospitalization risk. Lastly, the past infections variable, defined as stated above to capture the role of recently acquired immunity from infection in protecting from severe 240 disease upon reinfection, is equal to the total infection rate in the population summed over the 241 prior 4 to 16 weeks. This time window is explicit in the definition of RPI_i^t (see Appendix section 242 243 1.2).

A secondary set of analogous models treats RCIR as the response variable, namely the Pre-Delta-RCIR, the Delta-RCIR, the Omicron-RCIR, and the Omicron-Booster-RCIR. The first

three models adopt the same form as equation (1), while the Omicron-Booster-RCIR follows the same form as equation (2). To account for the sequential process leading to infections, all lags between dynamic covariates, and RCIR have been reduced by one week. This results in eight models, with four models fit to RCHR, and four models fit to RCIR. The exact formulation of models with RCIR as outcome variable are documented in Appendix section 2.6.

The selection of covariates for each model relies on correlation-based feature selection, taking 251 252 into account both Pearson's correlation between variables and the concurvity measures derived from GAMs. Details regarding feature selection can be found in Appendix sections 2.1 and 2.2. 253 The impact of each dynamic variable is quantified by computing the Accumulated Local effects 254 (ALE) of each smooth term on outcome variables. The local effect refers to the change in model 255 256 output when a particular input feature is changed while keeping all other features constant. The ALE method aggregates the local effects of each input feature across its entire range. By 257 accumulating these local effects, we gain insight into how changes in each input variable 258 influence the outcome variable across its entire range. Data processing, visualization, and 259 analysis were carried out using R 4.0 and Python 3.8. 260

261

262 **3. Results**

263 3.1 GAMs analysis for the relative case-hospitalization rate (RCHR) as the outcome



- Figure 1: Results for the Pre-Delta-RCHR (Blue), the Delta-RCHR (Orange), and the Omicron-
- 266 RCHR (Red). a-g: Accumulated local effects (ALE) of dynamic variables. Shaded areas in each
- 267 plot indicate 95% confidence intervals. h-k: Estimated slopes for each static variables, the upper
- and lower band indicate 95% confidence intervals. I: Deviance explained for each model. '***':
- 269 variable significant at p<0.001. '**': variable significant at p<0.01. '*': variable significant at p<0.05. ': variable significant at p>0.05.

In our analysis, we evaluated goodness-of-fit based on several metrics. For models with relative case-hospitalization risk (RCHR) as the outcome variable, the deviance explained ranges between 46.8% and 72.3% (Figure 11) for each variant wave. Moreover, we assessed the correlation between observed RCHR and predicted RCHR, which exhibited strong positive correlations ranging from 0.67 to 0.81 (Appendix section 3.1). These findings provide compelling evidence of the models' effectiveness in capturing and predicting the casehospitalization rate.

278 The relative completed primary series rate, and relative previous infections consistently 279 displayed strong negative associations with RCHR across different waves (Figures 1a and 1b). 280 Of particular note is that relative previous infections consistently ranked the highest in terms of 281 ALE across the different waves. Figure 1c reveals the impact of the relative government 282 response index gradually flattening out from the pre-Delta to the Omicron wave. Regarding 283 activity-related engagement levels, their effects on RCHR appear inconsistent across different 284 waves, as exemplified by the relative physician visits, which slightly changed from negative to positive effects as the analysis progressed from the pre-Delta to the Omicron wave (Figure 1e). 285 Lastly, the relative weekly testing rate served as a control variable to address the state-level 286 differences in testing rates. The result revealed a negative correlation between the relative 287 288 weekly testing rate and RCHR. Nevertheless, it is noteworthy that this association exhibited a decrease from the pre-Delta wave to the Omicron wave, as illustrated in Figure 1g. 289

Regarding the static variables, adults at high risk exhibited a declining positive association with RCHR. Additionally, states with higher Social Vulnerability Index (SVI) consistently showed higher RCHR. Among racial groups, the proportion of Black positively associated with RCHR during the Pre-Delta wave but did not exhibit a significant impact since the Delta wave. With healthcare systems variables, Medicaid spending per person consistently showed a negative association with RCHR.



298 Figure 2: Results of Omicron-Booster-RCHR for just the Omicron wave with the additional inclusion of an interaction effect between the relative completed primary series rate and the 299 300 relative booster rate. a: Two-dimensional contour plot for the interaction between relative completed primary series rate and relative booster rate. The deeper red indicates a more positive 301 302 effect on the RCHR, and the deeper blue indicates a more negative effect to the RCHR. b-g: 303 Accumulated local effects (ALE) of dynamic variables. Shaded areas in each plot indicate 95% confidence intervals. h: Estimated slopes for each static variables, the upper and lower band 304 indicate 95% condifence intervals. '***': variable significant at p<0.001. '**': variable 305 significant at p<0.01. '*': variable significant at p<0.05. ': variable significant at p>0.05. 306

With the exception of the completed primary series rate, the effects of all other variables 307 308 modeled in the Omicron-Booster-RCHR remained consistent with the results for the Omicron-RCHR shown in Figure 1. Figures 2a show the interaction between two vaccine-related variables 309 in a two-dimensional variable space. The solid black lines represent the contour lines. The 310 contour lines correspond to points that have an equivalent impact on the hospitalization rate, with 311 the values marked on each line indicating the actual interaction effect of these points on the 312 313 RCHR. Figure 2a reveals that the RCHR decreases along the direction of increasing the relative booster rate and the relative completed primary series rate. 314

315

297

316 3.2 GAMs analysis for the relative reported case-incidence rate (RCIR) as the outcome



Figure 3: Results for the Pre-Delta-RCIR (Blue), the Delta-RCIR (Orange), and the Omicron-RCIR (Red). a-g: Accumulated local effects (ALE) of dynamic variables. Shaded areas in each plot indicate 95% confidence intervals. h-k: Estimated slopes for each static variables, the upper and lower band indicate 95% condifence intervals. l: Deviance explained for each model. '***': variable significant at p<0.001. '**': variable significant at p<0.01. '*': variable significant at p<0.05. '': variable significant at p>0.05.

317

The GAMs using relative reported case-incidence rate (RCIR) as the outcome variable consistently demonstrate lower performance than those GAMs with RCHR as the outcome variable. Specifically, all GAMs for RCIR have deviance explained values below 40%, and correlations between observed RCIR and predicted RCIR range from 0.43 to 0.61 (Appendix section 3.2). The observed performance pattern indicates a more intricate and dynamic relationship concerning COVID-19 transmission, particularly evident during the Omicron wave.

Figure 3a illustrates a strong negative association between the relative completed primary series rate and RCIR during the Pre-Delta and Delta waves. However, this association vanished during the Omicron wave, coinciding with a decline in model performance (Figure 31). The ALE plot of the relative previous infection rate (Figure 2b) revealed an insignificant association between previous infection and RCIR during the pre-Delta and Delta waves but a significant negative association during the Omicron wave. Additionally, when the relative government policy index is greater than one, the ALE plots demonstrate a negative trend; however, the magnitude of this

effect is relatively smaller compared to other dynamic variables examined in the analysis.
Similar to GAMs for RCHR, the activity-related engagement levels exhibited inconsistent
patterns across different waves. Notably, the ALE of relative university visits reverses direction
from negative to positive between the pre-Delta wave and the later two waves.

- For the static variables, adults at high risk were consistently positively associated with RCIR across different waves. However, the other static variables, including racial groups, SVI, and healthcare expenditures, do not show a consistent or significant impact across different waves.
- 145 Incatticate experiationes, do not show a consistent of significant impact across unferent wave
- Figure 4 illustrates the results of the Omicron-Booster-RCIR for just the Omicron wave with the
- 345 additional inclusion of an interaction effect between the completed primary series rate and the
- relative booster rate. This interaction effect is presented as a dimension contour map in figure 4a.



Figure 4: Results of the Omicron-Booster-RCIR for just the Omicron wave with the additional 348 349 inclusion of an interaction effect between the relative completed primary series rate and the relative booster rate. a: Two-dimensional contour plot for the interaction between relative 350 completed primary series rate and relative booster rate. b-g: Accumulated local effects (ALE) of 351 dynamic variables. Shaded areas in each plot indicate 95% confidence intervals. h: Estimated 352 slopes for each static variables, the upper and lower band indicate 95% condifence intervals. 353 "***": variable significant at p<0.001. "*": variable significant at p<0.01. "*": variable 354 significant at p < 0.05. ": variable significant at p > 0.05. 355

356 The incorporation of the relative booster rate does not result in an improvement in the model fit;

the deviance explained for Model Omicron-Booster-RCIR remains at 17%. As depicted in Figure

4a, it is evident that only states with both a high relative completed primary series rate and a high relative booster rate exhibits a slightly negative impact, approximately -0.1, on the RCIR. The

findings from Model Omicron-RCIR, when combined with Omicron-Booster-RCIR, suggest that
 the covariates examined in this study do not contribute significantly to explaining the variation in
 RCIR during the Omicron wave. These results highlight the need for further research to identify

- 363 other factors that may better capture the dynamics of COVID-19 transmission during this 364 specific period.
- 365

366 **4. Discussion**

This analysis aims to characterize the relationship between population-level COVID-19 vaccine administration and pandemic-induced healthcare burdens, taking into account essential and confounding real-world processes. Our results point to three significant conclusions:

- Population-level vaccination is always significantly associated with reduced COVID-19
 case-hospitalization risk.
- Increased recent (1-4 months prior) infections are also consistently and strongly associated with reduced case-hospitalization risk.
- Local factors, activity-related engagement levels, and policy measures are important to the model's explanatory power, supporting the importance of considering these factors on population-level outcomes. However, their associations are inconsistent over time and across different variants.

378 Each of these conclusions is explained in more detail in the sections below. In each section, we 379 discuss the findings regarding case-hospitalization risk and compare them with the results related 380 to the reported case incidence rate. In general, our results strongly support the importance of 381 population-level vaccination and align with extant research on the role of acquired immunity in 382 reducing severe outcomes. However, it should be noted that the case incidence rate has a reduced 383 association with vaccination during the Omicron wave and much less consistently meaningful 384 associations with previous infection rates. Additionally, our analysis reflects the complexity of 385 the evolution of human behavior during the pandemic, given the dynamic role of activity-related 386 engagement levels and policy. It also supports the recognition of the epidemiological 387 vulnerability of socially and economically underserved communities.

4.1 Vaccines protect against COVID-19 case-hospitalization risk for pre-Delta, Delta and Omicron waves

Our study reveals a strong and statistically significant association between vaccine uptake rates and reduced COVID-19 case-hospitalization risk. This relationship was consistent across each of the variant waves modeled, and is consistent with earlier findings that vaccine protection against severe illnesses does not significantly wane in response to new variants. In contrast, when we modeled reported case-incidence rates as the response variable, we observed a decreasing effect of vaccines from the pre-Delta to the Omicron wave (Figure 3a). This outcome aligns with

existing literature highlighting the rapid waning of the vaccines' effectiveness against infection 396 [33,34]. Nonetheless, while vaccines may offer reduced protection against infection, our results 397 398 indicate that they continue to provide substantial protection against hospitalization risk and help alleviate the burden on healthcare systems. Additionally, although the value of booster shots for 399 400 protection against severe cases of COVID-19 is still being studied [35], results from our analysis 401 provide evidence supporting the effectiveness of booster doses against hospitalization risk 402 caused by the Omicron variant (Figure 2). Conversely, the findings obtained from our Omicron-Booster-RCIR model reveal that the interaction between the booster and completed primary 403 404 series rates has a relatively limited impact on Omicron infection (Figure 4). However, it is crucial to emphasize that despite the diminished effectiveness of mRNA boosters against 405 406 Omicron infections, vaccines still serve the essential purpose of reducing the harm of COVID-19 407 in the face of emerging variants.

408 4.2 Immunity from recent infection protects against COVID-19 case-hospitalization risk upon 409 reinfection

410 Higher past COVID-19 infection levels in a population are associated with a decrease in 411 COVID-19 case-hospitalization risk, indicating immunity gained from infection can provide 412 some protection against severe disease in the event of reinfection in the future, but only for a 413 limited period of time. Our study utilized the total number of cases reported in a 12-week 414 window, ranging from 4 to 16 weeks prior to the time period modeled, as a proxy for recently 415 acquired immunity, and found a strong negative association between the previous infection rate and future case-hospitalization risk. These results were consistent across the different variant 416 417 waves. This finding aligns with other case-control studies that found previous infections showed 418 strong effectiveness against severe, critical, or fatal COVID-19 [6,36]. Our analysis indicates that 419 prior infections from up to 6 months ahead are associated with decreased hospitalization risk, but 420 4 to 16 weeks has the strongest effect (see Appendix sections 2.4 and 2.5 for this sensitivity 421 analysis). While the waning of natural immunity has been established in molecular and clinical research [37], our analysis provides additional insight at the population-level. In our models with 422 423 case-incidence rate as the outcome variable, we found an insignificant association between previous infection and case-incidence rate during the pre-Delta and Delta waves. However, 424 during the Omicron wave, there was a significant negative association (Figure 3b). This finding 425 contrasts with existing literature that found, at the individual level, previous infection protected 426 against infection pre-Omicron, but this effectiveness decreases substantially during the Omicron 427 428 wave [38]. Nevertheless, at the population level, the number of infected individuals is 429 considerably higher during the Omicron wave than earlier, while a smaller proportion remains susceptible. Consequently, the cumulative impact of previous infections becomes more 430 pronounced. These results highlight that previous infections have a variable and inconsistent 431 432 impact on reinfection at the individual and population levels.

433 4.3 Local factors contribute to variation in COVID-19 health outcomes

434 Existing clinical and statistical studies [14,16,17] have identified critical indicators for COVID-

- 435 19 health outcomes including demographics, comorbidities, social vulnerability index (SVI), and
- 436 healthcare expenditures. Results from our model using RCHR as outcome variables indicate that

the SVI is positively associated with COVID-19 case-hospitalization risk across all variant 437 waves (Figure 1i). This finding is consistent with existing literature [14,17], which suggests that 438 439 individuals from socially vulnerable regions are more likely to experience harmful COVID-19 440 outcomes. For each new variant wave, the proportion of adults at high risk was less associated 441 with case-hospitalization risk than for the prior wave (Figure 1h). This result aligns with a cohort 442 study that the hazard ratio of hospital admissions with the Omicron variant, compared to the 443 Delta variant, showed a more significant drop in the elder age group compared to individuals 444 younger than 20 [39]. Our results reveal an insignificant association between black proportion 445 and case-hospitalization risk during the Delta and Omicron waves, which differs from previously identified positive associations across all waves [14]. In the United States, the eligibility for 446 447 Medicaid varies by state, but generally, individuals and families with incomes up to 138% of the 448 federal poverty level may qualify for coverage [40]. Our results reveal a consistent negative association between state-level Medicaid spending per person and COVID-19 case-449 hospitalization risk (Figure 1k), which indicates the potential protective effect of healthcare 450 451 expenditures in mitigating the impact of the pandemic on vulnerable groups. In contrast to the 452 case-hospitalization risk models, the case-incidence rate models indicate that there is no evidence 453 for consistent or significant associations with demographics, SVI, or healthcare expenditures 454 across variant waves, except for adults at high risk consistently positively associated with case-455 incidence rate (Figure 3). These results suggest that dynamic COVID-19 infection risk is complex and changes over time, and the factors contributing to transmission vary across waves. 456 457 Further research is needed for a more comprehensive understanding of the complex and evolving nature of COVID-19 transmission. 458

459 4.4 Activity-related engagement levels are associated with COVID-19 health outcomes

460 At the beginning of the pandemic, several studies evaluated the association between mobility and COVID-19 transmission with inconsistent findings [41,42]. One possible reason for this 461 462 inconsistency is that aggregated mobility data may not accurately reflect the risk of dynamically changing human behaviors, given that a minority of travel activities could be accountable for a 463 464 significant majority of infections [43]. Furthermore, the connection between mobility and harmful health outcomes remains unclear. Our study uses disaggregated mobility patterns to 465 capture diverse behaviors between populations, specifically relative activity-related engagement 466 levels, to explore the association between these variables and COVID-19 severity. To achieve 467 this, we divided activities into subcategories based on their purpose. University visits were used 468 469 to represent school-related activities, gym visits to signify high-risk indoor activities, and physician visits to indicate healthcare-related visits. 470

471 Results shown in Figure 1d indicate that the state-week pairs with relatively higher gym visits 472 are expected to observe higher case-hospitalization risk during the Pre-Delta wave. However, 473 this association did not reach statistical significance during the Delta and Omicron waves. In 474 contrast, when we modeled the case-incidence rate as the outcome variable, our analysis revealed 475 a minor effect of gym visits, as shown in Figure 3d. The positive impact of gym visits during the 476 Pre-Delta wave may be linked to infections among unvaccinated individuals engaging in indoor 477 activities. It is supported by existing research that unvaccinated individuals have a 2.6 times

higher likelihood of contracting SARS-CoV-2 than vaccinated individuals during indoor 478 activities [44]. Moreover, unvaccinated individuals exhibit a higher likelihood of hospitalization 479 480 [45], leading to a strong positive association between gym visits and case-hospitalization risk during the initial phases of vaccination distribution. In addition to indoor activity, we also 481 observed a significant association between case-hospitalization risk and overall visits to hospitals, 482 medical centers, and Outpatient Care Centers. Unlike indoor activity, this association 483 484 transitioned from negative to positive between the pre-Delta to Omicron wave. One possible explanation for this finding is that as the pandemic evolved, the public became more familiar 485 486 with the disease and more tolerant of at-home symptom management; thus, those COVID-19 487 patients that sought medical care were more likely to be those with more severe symptoms. 488 Finally, visits to the university were found to have a relatively minor impact on case-489 hospitalization risk. We hypothesize that this is due to the young and relatively healthy 490 demographic that frequents visiting schools, while still vulnerable to contracting the SARS-CoV-491 2 virus, they are less likely to experience severe outcomes from COVID-19 infection. This 492 hypothesis is further supported by the findings from the case-incidence rate model, which 493 identified a positive association with university visits during the Delta and Omicron waves 494 (Figure 3d). It is worth noting that during the Pre-Delta wave, school visits negatively impacted 495 the case-hospitalization risk. However, this impact changed to a positive association for the later 496 waves. These observations align with existing research, which has demonstrated that the younger 497 population exhibits the highest increase in susceptibility to the Delta variant compared to the pre-498 Delta variant [46].

499 4.5 More stringent government public health policy is associated with reduced COVID-19 500 case-hospitalization risk

501 Our results indicate that more stringent government policies were associated with reduced 502 COVID-19 case-hospitalization risk during the Pre-Delta and Delta wave. This is consistent with 503 previous studies [47]. In particular, we found that state-week pairs with a significantly high 504 government response index (indicating stricter policy) have a stronger negative effect on the 505 case-hospitalization risk (Figure 1c). However, this negative effect decreased over time, and was least evident during the Omicron wave. The reduced effect of the policy during Omicron is likely 506 due to a complex combination of factors, including the increasing population level immunity 507 from both widespread adoptions of vaccines and prior exposure providing more protection from 508 509 severe disease during this period, combined with a reduction in the government's response to the 510 pandemic over time.

511 Additionally, weekly testing rates were shown to be negatively associated with casehospitalization risk. While this result does not imply a causative relationship between testing rate 512 513 and COVID-19 severity, there are various reasons why testing rates may be linked to casehospitalization risk. Firstly, it represents a proxy input feature to capture the level of healthcare 514 515 infrastructure available to a population. Second, it directly impacts the reported case incidence 516 rate, as the number of reported cases in a region is a direct function of local testing availability, thus increased testing will lead to higher reported case rates, and lower case-hospitalization risk. 517 518 Third, increased testing can lead to more cases being identified, and thus impact people's

519 awareness and behavior during an outbreak. For these reasons testing rate is included as a 520 potential control factor in our model.

521

522 4.6 Limitations

523 As with all modeling studies, this work is subject to several limitations. Firstly, this study was 524 primarily designed to determine the association between various potential risk factors and COVID-19 outcomes, rather than to establish causality between these variables. Thus, our 525 526 findings may reflect the role of unobserved confounding factors excluded from our study. 527 Another potential limitation is due to the application at the state-level. The aggregation of the 528 data to the state-level is unable to capture the heterogeneities of the communities within each state, and it is possible that different associations exist at the local level, than are identified at the 529 530 state-level. Additionally, while we believe the use of the case-hospitalization risk in a given state at a given time is a plausible choice as a proxy for disease severity at an individual-level, and 531 532 captures the burden on the healthcare system at a population-level. However, it is subject to variable case reporting and data quality across states, which may arise due to uneven testing 533 534 capacity, reporting delays or at-home testing. Lastly, it is important to acknowledge that our 535 variable transformation, while facilitating a deeper understanding of relative changes, does come 536 with the inherent consequence of diminishing the original meaning these variables initially 537 conveyed.

538 5. Conclusions

539 This research utilizes publicly available real-world data to provide robust evidence of the 540 efficacy of vaccines against COVID-19 case-hospitalization risk across various variant waves in 541 the United States. More importantly, this paper concludes that booster shots offer additional 542 protection against severe COVID-19 during the Omicron waves. Despite the emergence of new 543 variants, vaccines remain the most effective intervention for mitigating the harm of COVID-19 544 and reducing burden on healthcare systems. Therefore, given the ongoing threat posed by 545 COVID-19 and its potential variants, vaccines continue to be the best line of defense for 546 protecting public health and preventing the further spread of the virus.

547

548 Availability of data and materials

- 549 All the data and code used for the analysis is available from 550 <u>https://github.com/hongru94/vaccination_rate_GAMs</u>.
- 551 Competing interests
- 552 The authors declare no potential conflicts of interest.
- 553 Funding
- 554 This work was funded the NSF RAPID Award ID 2108526, NSF Award ID 2229996, and 555 CDC Contract #75D30120C09570.
- 556 Author's Contributions

- 557 LG, and HD contributed to the conceptualization and design of the study. HD and SS collected
- the data and conducted the analysis. HD led the writing of the original draft. HD, SS, and LG
- edited the manuscript, discussed the results, and provided feedback regarding the manuscript. LG
- 560 supervised the study and acquired funding. HD and SS have verified the underlying data. All
- authors had full access to the data and approved the manuscript for publication.

562 Acknowledgments

- 563 We want to thank Maximilian Marshall for providing valuable insights and suggestions that have
- 564 contributed to enhancing the quality of this paper.
- 565

566 **Reference**

- 567 [1]Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the
 568 mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384:403–16.
 569 https://doi.org/10.1056/NEJMoa2035389.
- 570 [2]Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and Efficacy of
 571 Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med 2021;384:2187–201.
 572 https://doi.org/10.1056/NEJMoa2101544.
- [3]Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of
 the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 2021;385:1761–73.
 https://doi.org/10.1056/NEJMoa2110345.
- 576 [4]Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med
 577 2021;27:205–11. https://doi.org/10.1038/s41591-021-01230-y.
- 578 [5]Patel MK, Bergeri I, Bresee JS, Cowling BJ, Crowcroft NS, Fahmy K, et al. Evaluation of post579 introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health
 580 Organization. Vaccine 2021;39:4013–24. https://doi.org/10.1016/j.vaccine.2021.05.099.
- [6] Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of
 Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med
 2022;387:21–34. https://doi.org/10.1056/NEJMoa2203965.
- [7]Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of
 mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations,
 and deaths following a nationwide vaccination campaign in Israel: an observational study using
 national surveillance data. The Lancet 2021;397:1819–29. https://doi.org/10.1016/S01406736(21)00947-8.
- [8]Gram MA, Emborg H-D, Schelde AB, Friis NU, Nielsen KF, Moustsen-Helms IR, et al. Vaccine
 effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or
 Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. PLOS Med 2022;19:e1003992.
 https://doi.org/10.1371/journal.pmed.1003992.
- [9]Ng OT, Marimuthu K, Lim N, Lim ZQ, Thevasagayam NM, Koh V, et al. Analysis of COVID-19
 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated
 SARS-CoV-2 Vaccines With and Without Boosters in Singapore. JAMA Netw Open
 2022;5:e2228900. https://doi.org/10.1001/jamanetworkopen.2022.28900.
- 597 [10] Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19
 598 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national
 599 prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and
 600 Wales. The Lancet 2022;400:1305–20. https://doi.org/10.1016/S0140-6736(22)01656-7.
- [11] Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year
- of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis 2022;22:1293–302.
 https://doi.org/10.1016/S1473-3099(22)00320-6.

- [12] Wang R, Wang J, Hu T, Zhou X-H. Population-Level Effectiveness of COVID-19 Vaccination
 Program in the United States: Causal Analysis Based on Structural Nested Mean Model. Vaccines
 2022;10:726. https://doi.org/10.3390/vaccines10050726.
- 607 [13] Shioda K. Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution
 608 of Naturally Acquired Immunity n.d.
- [14] Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. Assessing COVID-19
 pandemic policies and behaviours and their economic and educational trade-offs across US states
 from Jan 1, 2020, to July 31, 2022: an observational analysis. The Lancet
 2023:S0140673623004610. https://doi.org/10.1016/S0140-6736(23)00461-0.
- 612 2023:S0140673623004610. https://doi.org/10.1016/S0140-6736(23)00461-0.
 613 [15] Hu S, Xiong C, Zhao Y, Yuan X, Wang X. Vaccination, human mobility, and COVID-19 health
- 614
 615 outcomes: Empirical comparison before and during the outbreak of SARS Cov-2 B.1.1.529
 615 (Omicron) variant. Vaccine 2023:S0264410X23006175.
- 616 https://doi.org/10.1016/j.vaccine.2023.05.056.
- 617 [16] Ogedegbe G, Ravenell J, Adhikari S, Butler M, Cook T, Francois F, et al. Assessment of
 618 racial/ethnic disparities in hospitalization and mortality in patients with COVID-19 in New York
 619 City. JAMA Netw Open 2020;3:e2026881–e2026881.
- 620 [17] Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID□19
 621 severity: a literature review. Rev Med Virol 2021;31:1–10.
- [18] Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time.
 Lancet Infect Dis 2020;20:533–4.
- 624 [19] HHS Protect Public Data Hub n.d. https://public-data-hub-dhhs.hub.arcgis.com/ (accessed January
 625 13, 2023).
- 626 [20] COVID-19/data_tables/vaccine_data/us_data at master · govex/COVID-19. GitHub n.d.
 627 https://github.com/govex/COVID-19 (accessed January 13, 2023).
- 628 [21] CDC. COVID Data Tracker. Cent Dis Control Prev 2020. https://covid.cdc.gov/covid-data-tracker
 629 (accessed January 13, 2023).
- 630 [22] COVID-19/data_tables/testing_data at master · govex/COVID-19. GitHub n.d.
 631 https://github.com/govex/COVID-19 (accessed January 13, 2023).
- [23] Places Data Curated for Accurate Geospatial Analytics | SafeGraph n.d. https://www.safegraph.com
 (accessed January 13, 2023).
- [24] Du H, Dong E, Badr HS, Petrone ME, Grubaugh ND, Gardner LM. Incorporating variant
 frequencies data into short-term forecasting for COVID-19 cases and deaths in the USA: a deep
 learning approach. EBioMedicine 2023;89:104482. https://doi.org/10.1016/j.ebiom.2023.104482.
- [25] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID-19 government response tracker
 (OxCGRT). Last Updat 2020;8:30.
- 639 [26] Bureau UC. State Population by Characteristics: 2010-2019. CensusGov n.d.
 640 https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-detail.html (accessed
 641 April 30, 2023).
- 642 [27] CDC/ATSDR SVI Data and Documentation Download | Place and Health | ATSDR 2022.
 643 https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html (accessed
 644 February 13, 2023).
- 645 [28] Adults at Higher Risk of Serious Illness if Infected with Coronavirus. KFF 2020.
 646 https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with 647 coronavirus/ (accessed February 13, 2023).
- [29] Health Insurance Coverage of the Total Population. KFF 2022. https://www.kff.org/other/state-indicator/total-population/ (accessed April 30, 2023).
- [30] Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID's role in pandemic
 response. China CDC Wkly 2021;3:1049.
- [31] Quesada JA, López-Pineda A, Gil-Guillén VF, Arriero-Marín JM, Gutiérrez F, Carratala-Munuera
 C. Incubation period of COVID-19: A systematic review and meta-analysis. Rev Clínica Esp Engl
 Ed 2021;221:109–17. https://doi.org/10.1016/j.rceng.2020.08.002.

- [32] Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between
 symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19
 patients. Int J Environ Res Public Health 2020;17:7560.
- Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman L, Haas EJ, et al. Waning
 Immunity after the BNT162b2 Vaccine in Israel. N Engl J Med 2021;385:e85.
 https://doi.org/10.1056/NEJMoa2114228.
- [34] Tenforde MW, Self WH, Naioti EA, Ginde AA, Douin DJ, Olson SM, et al. Sustained effectiveness
 of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among
 adults—United States, March–July 2021. Morb Mortal Wkly Rep 2021;70:1156.
- [35] Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID 19
 booster dose vaccination against the Omicron variant: A systematic review. J Med Virol
 2022;94:2969–76.
- [36] Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, et al. Protection
 against omicron (B. 1.1. 529) BA. 2 reinfection conferred by primary omicron BA. 1 or pre-omicron
 SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a testnegative case-control study. Lancet Infect Dis 2023;23:45–55.
- [37] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous
 SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a
 systematic review and meta-regression. Lancet Infect Dis 2023;23:556–67.
 https://doi.org/10.1016/S1473-3099(22)00801-5.
- [38] Altarawneh HN, Chemaitelly H, Hasan MR, Ayoub HH, Qassim S, AlMukdad S, et al. Protection
 against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med 2022;386:1288–
 90. https://doi.org/10.1056/NEJMc2200133.
- [39] Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative
 analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529)
 and delta (B.1.617.2) variants in England: a cohort study. The Lancet 2022;399:1303–12.
 https://doi.org/10.1016/S0140-6736(22)00462-7.
- [40] Blavin F, Karpman M, Kenney GM, Sommers BD. Medicaid versus marketplace coverage for near-poor adults: effects on out-of-pocket spending and coverage. Health Aff (Millwood) 2018;37:299–
 307.
- [41] Badr HS, Du H, Marshall M, Dong E, Squire MM, Gardner LM. Association between mobility
 patterns and COVID-19 transmission in the USA: a mathematical modelling study. Lancet Infect
 Dis 2020;20:1247–54.
- [42] Kraemer MU, Yang C-H, Gutierrez B, Wu C-H, Klein B, Pigott DM, et al. The effect of human mobility and control measures on the COVID-19 epidemic in China. Science 2020;368:493–7.
- [43] Chang S, Pierson E, Koh PW, Gerardin J, Redbird B, Grusky D, et al. Mobility network models of
 COVID-19 explain inequities and inform reopening. Nature 2021;589:82–7.
 https://doi.org/10.1038/s41586-020-2923-3.
- [44] Wienkes H, Vilen K, Lorentz A, Gerlach D, Wang X, Saupe A, et al. Transmission of and Infection
 With COVID-19 Among Vaccinated and Unvaccinated Attendees of an Indoor Wedding Reception
 in Minnesota. JAMA Netw Open 2022;5:e220536.
- https://doi.org/10.1001/jamanetworkopen.2022.0536.
- [45] Havers FP, Pham H, Taylor CA, Whitaker M, Patel K, Anglin O, et al. COVID-19-Associated
 Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States,
 January 2021 to April 2022. JAMA Intern Med 2022;182:1071.
 https://doi.org/10.1001/jamainternmed.2022.4299.
- [46] Chun JY, Jeong H, Kim Y. Age-Varying Susceptibility to the Delta Variant (B.1.617.2) of SARS CoV-2. SSRN Electron J 2021. https://doi.org/10.2139/ssrn.3951778.
- [47] Hale T, Angrist N, Hale AJ, Kira B, Majumdar S, Petherick A, et al. Government responses and
 COVID-19 deaths: Global evidence across multiple pandemic waves. PLoS One 2021;16:e0253116.
- 706
- 707

medRxiv preprint doi: https://doi.org/10.1101/2023.06.14.23291388; this version posted October 29, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. Supplementary Materials for Association between vaccination rates and COVID-19 health outcomes in the United States: a population-level statistical analysis Hongru Du MS^{1,2, *}, Samee Saiyed MSE^{1,2}, and Lauren M. Gardner PhD^{1,2,3} ¹Center for Systems Science and Engineering, Johns Hopkins University, Baltimore, MD 21218, USA. ²Department of Civil and Systems Engineering, Johns Hopkins University, Baltimore, MD 21218, USA. ³Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA. *Corresponding author. Johns Hopkins University, 3400 N. Charles Street, Shaffer 4, Baltimore, MD, 21218, USA. E-mail address: hdu9@jhu.edu (Hongru Du)

728 Table of Contents

729	1. Supplementary Data	23
730	1.1 Preprocessing of genomic data	23
731	1.2 Variables description	24
732	1.3 Preprocessing of mobility data	28
733	2. Supplementary Methods	29
734	2.1 Static variables selection	29
735	2.2 Dynamic variables selection	29
736	2.3 Robustness check of vaccination data	30
737	2.4 Sensitivity analysis of prior window length for previous infection	31
738	2.5 Sensitivity analysis of lags for previous infection	32
739	2.6 GAMs with reported case-incidence rate (RCIR) as the outcome variable	33
740	3. Supplementary Results	33
741	3.1 Models evaluation for GAMs with RCHR as outcome variable	33
742 743	3.2 Models evaluation for GAMs with RCIR as outcome variable	38

744 745 746

747 1. Supplementary Data

748 1.1 Preprocessing of genomic data

All genomic data were collected from GISAID [1] on October 27th, 2022. GISAID is a publicly accessible repository 749 750 of dataset that sharing of genomic data on various pathogens, including influenza and COVID-19. We analyzed the 751 available set of sequences, to determine the proportion of each variant theoretically in circulation. Specifically, we 752 calculated the proportion of each variant for each week in each state from March 1st, 2021, to March 1st, 2022. To 753 identify the most dominant variant for each state-week pair during the analyzed period, we labeled the state-week 754 pairs based on the variant with the highest proportion. This enables us to track the dominant variant in each state and 755 cluster the state-week pairs based on the most dominant variant. The assignment of state-week pairs is shown in 756 Appendix figure S1 below:

757

758 759



Appendix figure S1: State-week group assignment based on the dominant variant. The x-axis represents each week,the y-axis represents each state, and the color represents the assignment of each state-week pair.

762	
763	
764	
765	
766	
767	
768	1.2 Variables description
	^

769 *Outcome variable*

Case-hospitalization risk: In this study we used case-hospitalization risk (CHR_i^t) as the outcome variable of interest for our model. COVID-19 case-hospitalization risk represent both the severity of COVID-19 disease at an individual level and the burden it places on the healthcare system. Case-hospitalization risk (CHR_i^t) for each state *i* and week *t* is defined as follow:

774

780

 $CHR_i^t = \frac{H_i^t}{c_i^{t-1}},$

where H_i^t is the number of hospitalizations for state *i* and week *t* and C_i^{t-1} is the number of confirmed cases for state *i* and week t - 1. We applied a one-week lag between reported confirmed cases and hospitalizations to account for the time between symptom onset and hospital admission [2]. Weekly state-level CHR_i^t was treated as the outcome variable in this analysis and served as an indicator for the burden of COVID-19 risk for a given time and location.

781 Dynamic Covariates

782 Vaccination rate: In this analysis, the weekly cumulative COVID-19 vaccination rate is the primary variable under 783 examination, as we hypothesize it to be a critical determinant in protecting populations against severe COVID-19 784 disease. The completed primary series rate was chosen over the partial vaccination rate because it represents the 785 recommended dosage by the U.S. CDC. To address the fact that vaccine eligibility was not available to all U.S. adults until April 19th, 2021, we also ran the model using the partial vaccination rate for the pre-Delta waves, and the 786 787 results are consistent with the completed primary series rate (results are presented in Appendix section 2.3). As 788 booster shots became widely available during the Omicron wave, we also include the booster vaccination rate as a 789 covariate to investigate its potential impact on COVID-19 health outcomes. Due to errors and anomalies in the data, 790 the vaccination data excludes West Virginia and New Hampshire, while the booster vaccination data excludes West 791 Virginia, New Hampshire, and North Carolina. As a result, West Virginia and New Hampshire are excluded from all 792 analyses, and North Carolina is excluded from the booster analysis for the Omicron wave.

793 Activity-related engagement level: We adapted multiple mobility-derived metrics from a previous study [3] to 794 represent destination-specific travel behaviors and activity-related engagement levels for specific types of activities, 795 namely gym, university, and physician visits. Specifically, the engagement levels represent the weekly number of 796 visits to a given destination of interest per person per week. This variable allows us to compare the relative 797 frequency of visits to each point of interest across states and to investigate their potential impact on COVID-19 798 health outcomes. The metrics were generated based on anonymized mobility data from Safegraph [4], which tracks 799 the number of visits to different types of destinations for a sample of the population at the census tract level in the 800 U.S. Examples of destinations include full-service restaurants, gyms, and grocery stores. The original Safegraph 801 dataset includes over 20 destination categories; thus, to reduce the complexity of the model we identified a smaller 802 representative set of destinations to include as input in the final model. This was accomplished by first organizing 803 the destination categories into six distinct destination groups based on the first two digits of the NAICS code [5], 804 namely Retail Trade (44-45), Education Services (61), Healthcare and Social Assistance (62), Arts, Entertainment, 805 and Recreation (71), Accommodation and Food Services (72), and Other Services (81). From each group, we 806 selected one destination category as the representative variable for the group based on the correlations between other 807 variables within the group (Details are documented in Appendix section 1.4). Subsequently, we conducted a model

808 selection process to identify the most appropriate subset of mobility variables from these six to be included in the 809 final model based on concurvity and significane level (details are documented in Appendix section 2.2).

810 Previous infection rates: Several studies have demonstrated the effectiveness of previous infections against

811 reinfections and severe COVID-19 outcomes. Studies have illustrated that individuals retain a substantial level of

natural immunity for six months after infection [6–8]. To attempt to account for the role of recently acquiredimmunity from infection in protecting from severe disease upon reinfection in our study we generate a variable to

represent the total population infected and recovered within a recent window, i.e., the total infections reported

between weeks (t-16) and (t-4), which allows for time to recover and build up immunity [9] by the time period t at

816 which the hospitalizations are modeled, but short enough that immunity has not waned. These specific prior

817 infections variable (PI_i^t) , requires multiple parameters, namely the length of the interval that infections are summed

818 over and the start and end period of the window. To identify the best window and evaluate the sensitivity of our

819 analysis to the chosen window length, start and end time, we conducted a sensitivity analysis. The time window with

820 the largest deviance explained in the GAMs was selected for the final model, which was a three-month window

821 ranging from 4 to 16 weeks prior to time t. Additional details of this sensitivity analysis and the results are included

822 in Appendix section 2.4. The mathematical formulation of this metric is defined as follows:

$$PI_i^t = \frac{\sum_{j:t-16}^{t-4} C_i^j}{pop_i}$$

823 where PI_i^t represents cumulative infection rate for state *i* from 16 to 4 weeks prior of week t, C_i^j is the weekly 824 confirmed cases for state *i* at week *j*, and *pop_i* is the population for state *i*. The sum in the numerator defines the 825 summation of C_i^j for the t - 16 to t - 4 weeks prior to t.

826 Government policy: The stringency and timing of implementing government policies to mitigate the impacts of 827 COVID-19, such as school closure, cancellation of public events, and international travel controls, are associated 828 with different measures of epidemic severity [10]. We selected the government response index from Oxford 829 Coronavirus Government Response Tracker (OxCGRT) [11] as our indicator for government policy. The index 830 tracks the diversity of government responses across various policies, ranging from containment measures and 831 closures to healthcare systems, vaccination strategies, and economic policies. This index reflects the government's 832 response level with a number ranging from 0 to 100, the larger the number, the more substantial the response. It is 833 available for all 50 states in the U.S. at a weekly timescale for the entire period of analysis.

834 Weekly testing rate: The weekly testing rates were included in the model as a potential confounding factor for 835 multiple reasons. Firstly, it represents a proxy input feature to capture the level of healthcare infrastructure available 836 to a population. Second, it directly impacts the case-hospitalization risk through the denominator (i.e., total reported 837 cases), as the number of reported cases in a region is a direct function of local testing availability, thus increased 838 testing will lead to higher reported case rates, and lower case-hospitalization risk. For example, in two locations with 839 the same true case-hospitalization risk (e.g., the likelihood of a COVID-19 infection needing admittance is equal), a 840 location with twice as much testing will detect more cases, and therefore appear to have a lower case-hospitalization 841 risk. Third, increased testing can lead to more cases being identified, and thus impact people's awareness and 842 behavior during an outbreak. For these reasons testing rate is included as a potential confounding factor in our model.

843 We normalized the raw weekly total testing count by population to get the weekly testing rate.



845

Appendix figure S2: Visualization of dynamic variales before variable transformation (a1 to h1) and after variable
transformation (a2 to h2). For the y-axis label, the abbreviations signify the following variables: CHR: Casehospitalization risk, CPSR: Completed primary series rate, PI: Previous infection, GR: Government policy measure,
WTR: Weekly testing rate, UV: University visits, GV: Gym visits, PV: Physician visits.

865 Static Covariates

866 Appendix table S1: Full list of static variables.

Variable name	Variable description	source
Static variables	·	
Black	The proportion of the population identified as non-Hispanic Blacks.	[13]
proportion		
Medicaid	Total Medicaid spending in kilo for each state normalized by the population.	[14]
spending		
Healthcare	Total Healthcare spending in kilo for each state normalized by the population.	[15]
spending		
Poverty rate	Percentage of population living below poverty line.	[16]
Social	The Social Vulnerability Index utilizes data from the U.S. Census to assess the relative	[17]
Vulnerability	level of social vulnerability in each census tract. By analyzing 14 social factors, the SVI	
Index	categorizes tracts into four closely interrelated themes and then aggregates them as a	
	single indicator of social vulnerability.	
HAQI	IHME's healthcare access and quality index.	[18]
Republican	Percentage of a state's voters who voted for the 2020 Republican presidential	[19]
voters	candidate.	
Adults at high	The proportion of the population over 18 years old is at high risk of serious illness if	[20]
risk	infected with Coronavirus.	
Proportion over	Proportion of population age 65 and older.	[20]
65		

- 891
- 892
- 000
- 893
- 894

895 *1.3 Preprocessing of mobility data*

The 21 mobility destination categories from Safegraph were organized into six distinct industry groups based on the
NAICS code. The relevant groups per the NAICS code are Retail Trade (44-45), Education Services (61),
Healthcare and Social Assistance (62), Arts, Entertainment, and Recreation (71), Accommodation and Food
Services (72), and Other Services (81).² The details of generating visits to each POI are documented in previous
publication.

901

902 Appendix table S2: Description of each industry group and the corresponding destination categories.

Retail Trade (44-	Education	Healthcare	Arts,	Accommodation	Other Services
45)	Services (61)	and Social	Entertainment,	and Food Services	(81)
		Assistance	and Recreation	(72)	
		(62)	(71)		
	Elementary	Office of	Parks (712190)	Hotels (721110)	Religious
Automotive Store	School	Physician			Organizations
(441310)	(611110)	(621111)			(813100)
		Child Day	Gym (713940)	Full-Service	
Hardware Store	University	Care (624410)		Restaurant	
(444130)	(611310)			(722511)	
Grocery Store				Cafes, Snacks, Bars	
(445110)				(722515)	
				Limited-Service	
Convenience				Restaurant	
Store (445120)				(722513)	
Pharmacies					
(446110)					
Gas Station					
(447110)					
Sporting Goods					
Store (451110)					
Department Store					
(452210)					
Other General					
Store (452319)					
Used					
Merchandise					
Store (453310)					

903

904 To reduce the complexity of the model, we selected one destination category as the representative variable for each 905 industry group. For the industry groups with more than 3 destination categories, we conducted a Pearson's 906 correlation analysis and selected the variable that had the highest correlation to the other destination categories in 907 each group. This method selected Gas Stations and Full-Service Restaurant from the Retail Trade (44-45) and 908 Accommodation and Food Services (72) as the representative variable for each industry group. For the Educational 909 Services (61) and Healthcare and Social Assistance (62) groups, we selected University and Office of Physician as 910 the representative variables based on studies that indicated SARS-CoV-2 infection severity is lower in adolescents 911 than adults.³ For the Arts, Entertainment, and Recreation (71) industry group, we selected Gym as the representative 912 variable instead of Parks because studies have identified park use to have a minor effect on COVID-19 transmission

- 913 compared to other mobility destinations.⁴ Religious Organizations was selected from the Other Services (81)
- 914 industry group because it is the only destination category present.

915 2. Supplementary Methods

916 2.1 Static variables selection

917 We selected state-level static variables that were found to have association with COVID-19 health outcomes in a

- 918 recent study [12]. These variables cover a ranging of different factors, such as socioeconomic indicators, racial
- 919 demographics, age, proxy for comorbidities, political factors, and state-level healthcare expenditures. Then, a
- 920 correlation analysis is performed within static variables to determine the suitable variables to be included in the
- model. Full list of static variables included in the correlation analysis are listed in Appendix table S1.
- 922



Static Variables Correlation Heatmap

923

924 Appendix figure S3. Pearson's correlation heatmap between each pair of static variables.

925

926 Based on the correlation analysis, the set of static variables to be incorporated into the models was determined. We 927 selected the black proportion as a representative variable for the race group and the SVI as a proxy for the 928 vulnerable population. The poverty rate was dropped due to its high correlation with SVI. Additionally, we selected 929 adults at high risk as a control variable for population-level comorbidities and dropped the proportion over 65. We 930 also decided to include Medicaid spending over healthcare spending as the state-level proxy for healthcare 931 expenditures. Lastly, we dropped the HAQI and Republican voters variables due to their high correlation with the 932 completed primary series rate.

- 933
- 934
- 935
- 936

937 2.2 Dynamic variables selection

938 The GAMs fit outcome variables with smoothed independent variables, allowing the nonlinear relationships
939 between input and output. However, the nonlinear variables smoothing sometimes can result in concurvity issues.
940 Concurvity occurs when some smooth term in a model could be approximated by one or more of the other smooth

941 terms, leading to inaccurate estimates of the effect for given variables. In this section, we conduct model selection to

- 942 ensure the validity of our model and to detect and mitigate any concurvity issues that may arise, using mobility data
- selected from Appendix section 1.4 and other independent variables. The significance level and the concurvity for
- each variable for every model are reported in table S2 below:
- 945

946 Appendix table S3: Significance level and concurvity for all dynamic variables.

	Pre-Delta w	ave	Delta wave	e	Omicron way	e
/ariable	Signif	Concurvity	Signif	Concurvity	Signif	Concurvity
Relative completed primary series rate	***	0.71	***	0.79	***	0.81
Relative previous infection rate (12 weeks)	***	0.62	***	0.31	***	0.41
Relative full-service restaurant rate		0.82		0.81	*	0.86
Relative gas station visits		0.91		0.85	**	0.89
Relative religious organization visits	***	0.84		0.84	**	0.87
Relative gym visits	***	0.69	**	0.76		0.76
Relative university visits	*	0.80	***	0.62	***	0.64
Relative office of physician visits	***	0.70		0.65	**	0.68
Relative weekly testing rate	***	0.81	***	0.64	***	0.57
Relative government response index	***	0.78	***	0.32		0.27
Relative weekly testing rate Relative government response index	***	0.81 0.78	***	0.64 0.32	***	0.57

⁹⁴⁸

The value of concurvity range from 0 to 1, the higher the concurvity the more a smooth variable can be approximated by the smooth of other variables. Specifically, a concurvity value above 0.8 generally signals the need for careful inspection of the model. Based on the results form table S3, we removed relative full-service restaurant, relative gas station, and relative religious organization visits from the model. This decision was based on their lack of significance and/or their high concurvity values. The equivalent results for selected variables are presented in table S3.

955

956 Appendix table S4: Significance level and concurvity for selected variables.

	Pre-Delta wave		Delta wav	Delta wave		Omicron wave	
Variable	Signif	Concurvity	Signif	Concurvity	Signif	Concurvity	
Relative completed primary series rate	***	0.63	***	0.61	***	0.60	
Relative previous infection rate (12 weeks)	***	0.59	***	0.25	***	0.35	
Relative gym visits	***	0.54		0.57		0.56	
Relative university visits		0.69	***	0.49	***	0.44	
Relative office of physician visits	***	0.66		0.60	**	0.64	
Relative weekly testing rate	***	0.78	***	0.51	***	0.51	
Relative government response index	***	0.72	***	0.26	*	0.23	

957

958 Significance codes: '***': 0.001, '**': 0.01, '*': 0.05, '.': 0.1, '': > 0.1.

959 The results from table S4 reveal that each variable exhibits a concurvity value below 0.8 and is significant in at least 960 one out of three models.

961

962 2.3 Robustness check of vaccination data

We selected the completed primary series rate as the main vaccination variable in the main analysis. To assess the robustness and validity of our findings, we conducted additional analyses using different vaccination data (completed primary series rate, and partial vaccination rate) and varying starting dates (March 8th, 2021, and April 19th, 2021) for the analysis. We applied our sensitivity analysis to Model Pre-Delta-RCHR, as it is the only ones that could be affected by the analysis. The results of four different combination of vaccination data and starting date for Model Pre-Delta-RCHR are shown in Appendix figure S4 below:

⁹⁴⁷ Significance codes: '***': 0.001, '**': 0.01, '*': 0.05, '.': 0.1, '': > 0.1.





970 Appendix figure S4: Robustness check of vaccination rate with different vaccination data and varying starting date971 for Model Pre-Delta-RCHR.

972

973 The finding from this robustness check demonstrated a strong and consistent impact of vaccination, independent of 974 the chosen vaccination data or the starting date of the analysis. This consistency suggests the robustness of our 975 results and highlights the robustness of the completed primary series rate as the main vaccination variable. 976

976

977 2.4 Sensitivity analysis of prior window length for previous infection

978 In this section, we presented a sensitivity analysis to assess the impact of the prior window length for the previous 979 infection on our analysis. To ensure our results are robust, we fixed all other covariates and a lag of four weeks for 980 previous infections while varying the prior window length for previous infections from 12 to 24 weeks. The results 981 of this sensitivity analysis for each model are shown below:



983	Appendix figure S5: Comparison of accumulated local effects of the previous infection rate for Model Pre-Delta-
984	RCHR (a), Delta-RCHR (b), and Omicron-RCHR (c) with different prior window lengths (12, 16, 20 and 24 weeks).
985	
986	
987	
988	
989	
990	
991	
992	
993	
994	
995	
996	
997	
998	2.5 Sensitivity analysis of lags for previous infection

999 This section presents a sensitivity analysis to assess the impact of the prior window length for the previous infection 1000 on our analysis. To ensure our results are robust, we fixed all other covariates and a prior window length of 12 1001 weeks for previous infections while varying the lag for previous infections from 4 to 16 weeks. The results of this 1002 sensitivity analysis for each model are shown below: 1003



1004

Appendix figure S6: Comparison of the accumulated local effects of the previous infection rate for Model Pre-Delta RCHR (a), Delta-RCHR (b) and Omicron-RCHR (c) with different lags (4, 8, 12, and 16 weeks).

- 1007
- 1008
- 1009
- 1010
- 1012

1013

1014 2.6 GAMs with reported case-incidence rate (RCIR) as the outcome variable

1015 These GAMs share the same framework as Model Pre-Delta-RCHR, Delta-RCHR, and Omicron-RCHR, while the 1016 outcome variable is the reported case-incidence rate (RCIR). To account for the sequential process leading to 1017 infections, all lags between dynamic covariates and RCIR have been reduced by one week. These three GAMs have 1018 the form:

1019

$\begin{aligned} RCIR_i^t &\sim Gamma(\mu, \phi) \\ \log(\mu) &= \alpha + f_1(RCPSR_i^{t-1}) + f_2(RWTR_i^{t-1}) + f_3(RGV_i^{t-1}) + f_4(RPV_i^{t-1}) \\ f_5(RUV_i^{t-1}) &+ f_6(RGP_i^{t-1}) + f_7(RPI_i^t) + \beta_1(Black \ proportion) + \\ \beta_2(SVI) &+ \beta_3(Proportion \ of \ adults \ at \ high \ risk) + \beta_4(Medicaid \ spending) \end{aligned}$

1020

1021 Where α represents the intercept, β_i represent the parametric coefficients of each static variable, and f_i are spline 1022 smooth functions of the relative dynamic variables. Additionally, a model is constructed for the Omicron wave, 1023 incorporating an interaction between completed primary series and booster rate (Omicron-Booster-RCIR). The 1024 model Omicron-Booster-RCIR has the form:

1025

$$RCIR_{i}^{t} \sim Gamma(\mu, \phi)$$

$$\log(\mu) = \alpha + f_{1}(RCPSR_{i}^{t-1}, RBR_{i}^{t-1}) + f_{2}(RWTR_{i}^{t-1}) + f_{3}(RGV_{i}^{t-1}) + f_{4}(RPV_{i}^{t-1})$$

$$f_{5}(RUV_{i}^{t-1}) + f_{6}(RGP_{i}^{t-1}) + f_{7}(RPI_{i}^{t}) + \beta_{1}(Black \ proportion) + (S2)$$

$$\beta_{2}(SVI) + \beta_{3}(Proportion \ of \ adults \ at \ high \ risk) + \beta_{4}(Medicaid \ spending)$$

1026

1027 Where f_1 represent a smooth interaction function between $RCPSR_i^{t-2}$ and RBR_i^{t-2} . For all the mentioned models 1028 above, the weekly state-level RCHR is assumed to follow a Gamma distribution with a log link. This choice of the 1029 Gamma family accounts for the positively skewed distribution of the outcome variable. We use thin plate regression 1030 splines as the smoothing basis for all f_i and set the basis dimension to three to maximize the interpretability of the 1031 models.

- 1033
- 1034
- 1035
- 1036
- 1037
- 1038
- 1039
- 1040
- **1041 3. Supplementary Results**
- 1042 3.1 Models evaluation for GAMs with RCHR as outcome variable
- 1043



1044 1045 Appendix figure S7: Model diagnostic plots for Model Pre-Delta-RCHR. The correlation coefficient between fitted 1046 RCHR and predicted RCHR is 0.78.



Appendix figure S8: Model diagnostic plots for Model Delta-RCHR. The correlation coefficient between fitted RCHR and predicted RCHR is 0.67.





Appendix figure S9: Model diagnostic plots for Model Omicron-RCHR. The correlation coefficient between fittedRCHR and predicted RCHR is 0.81.





Appendix figure S10: Model diagnostic plots for Model Omicron-Booster-RCHR. The correlation coefficient
 between fitted RCHR and predicted RCHR is 0.83.

3.2 Models evaluation for GAMs with RCIR as outcome variable



Appendix figure S11: Model diagnostic plots for Model Pre-Delta-RCIR. The correlation coefficient between fitted RCHR and predicted RCHR is 0.57.



Appendix figure S12: Model diagnostic plots for Model Delta-RCIR. The correlation coefficient between fitted
 RCHR and predicted RCHR is 0.61.





Appendix figure S13: Model diagnostic plots for Model Omicron-RCIR. The correlation coefficient between fitted
 RCHR and predicted RCHR is 0.43.







Appendix figure S14: Model diagnostic plots for Model Omicron-Booster-RCIR. The correlation coefficient
 between fitted RCHR and predicted RCHR is 0.44.

1212 **Reference**

- 1213 [1] Khare S, Gurry C, Freitas L, Schultz MB, Bach G, Diallo A, et al. GISAID's role in pandemic response.
 1214 China CDC Wkly 2021;3:1049.
- 1215 [2] Faes C, Abrams S, Van Beckhoven D, Meyfroidt G, Vlieghe E, Hens N, et al. Time between symptom onset, hospitalisation and recovery or death: statistical analysis of Belgian COVID-19 patients. Int J Environ Res Public Health 2020;17:7560.
- [3] Du H, Dong E, Badr HS, Petrone ME, Grubaugh ND, Gardner LM. Incorporating variant frequencies data into short-term forecasting for COVID-19 cases and deaths in the USA: a deep learning approach. EBioMedicine 2023;89:104482. https://doi.org/10.1016/j.ebiom.2023.104482.
- [4] Places Data Curated for Accurate Geospatial Analytics | SafeGraph n.d. https://www.safegraph.com (accessed January 13, 2023).
- 1223 [5] NAICS & SIC Identification Tools. NAICS Assoc n.d. https://www.naics.com/search/ (accessed April 6, 2023).
- 1224 [6] Altarawneh HN, Chemaitelly H, Ayoub HH, Tang P, Hasan MR, Yassine HM, et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. N Engl J Med 2022;387:21–34. https://doi.org/10.1056/NEJMoa2203965.
- [7] Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, et al. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. N Engl J Med 2022;386:2201–12.
 https://doi.org/10.1056/NEJMoa2118946.
- [8] Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C, et al. Protective effectiveness of previous SARS-CoV-2
 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 2023;23:556–67. https://doi.org/10.1016/S1473-3099(22)00801-5.
- 1233 [9] Abrahim SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, et al. Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia. PLOS ONE 2020;15:e0244269. https://doi.org/10.1371/journal.pone.0244269.
- 1236 [10] Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, et al. Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 2020;4:1303–12.
- 1238 [11] Hale T, Webster S, Petherick A, Phillips T, Kira B. Oxford COVID-19 government response tracker
 (OxCGRT). Last Updat 2020;8:30.
- 1240 [12] Bollyky TJ, Castro E, Aravkin AY, Bhangdia K, Dalos J, Hulland EN, et al. Assessing COVID-19 pandemic
 policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to
 July 31, 2022: an observational analysis. The Lancet 2023:S0140673623004610.
 https://doi.org/10.1016/S0140-6736(23)00461-0.
- 1244 [13] Bureau UC. State Population by Characteristics: 2010-2019. CensusGov n.d.
 1245 https://www.census.gov/data/datasets/time-series/demo/popest/2010s-state-detail.html (accessed April 9, 2023).
- 1247[14]Total Medicaid Spending. KFF 2022. https://www.kff.org/medicaid/state-indicator/total-medicaid-spending/1248(accessed February 13, 2023).
- 1249 [15] Health Care Expenditures by State of Residence (in millions). KFF 2022. https://www.kff.org/other/state-indicator/health-care-expenditures-by-state-of-residence-in-millions/ (accessed February 13, 2023).
- 1251[16]Poverty Rate by Race/Ethnicity. KFF 2022. https://www.kff.org/other/state-indicator/poverty-rate-by-
raceethnicity/ (accessed February 13, 2023).
- [17] CDC/ATSDR SVI Data and Documentation Download | Place and Health | ATSDR 2022.
 https://www.atsdr.cdc.gov/placeandhealth/svi/data_documentation_download.html (accessed February 13, 2023).
- 1256[18]Global Burden of Disease (GBD). Inst Health Metr Eval 2014. https://www.healthdata.org/gbd (accessed
April 9, 2023).
- 1258 [19] Harvard Dataverse. Harv Libr n.d. https://library.harvard.edu/services-tools/harvard-dataverse (accessed April 9, 2023).
- 1260 [20] Adults at Higher Risk of Serious Illness if Infected with Coronavirus. KFF 2020.
- https://www.kff.org/other/state-indicator/adults-at-higher-risk-of-serious-illness-if-infected-with-coronavirus/ (accessed February 13, 2023).

1263